Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Chief Medical Officer | July 19, 2022 | July 21, 2022 |
| NEOGENOMICS INCNEO · Entity 2096 | Director | June 01, 2025 | June 03, 2025 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | EVP, Chief Medical Officer | July 08, 2026 | July 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date July 19, 2022 · Filed July 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,898 |
Last balance in matching sequence
After 2022-07-20 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-07-19 · Grant · Acquired 15,000 · Balance 37,500 F1: Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested. F2: Includes 22,500 restricted stock units. Row 2 · 2022-07-20 · Sale · Disposed 5,602 · Balance 31,898 F3: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer. F2: Includes 22,500 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested.
F2: Includes 22,500 restricted stock units.
F3: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer.
NEOGENOMICS INC
Report date June 01, 2025 · Filed June 03, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 131,023 |
Reported balance
After 2025-06-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-06-01 · Exercise / conversion · Acquired 12,254 · Balance 131,023 F1: Due to clerical error, this amendment to Form 4 is being filed to correct the transaction code in the reported transaction. F2: As reported in the original Form 4, reflects the release of restricted stock units that were previously reported on a Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Due to clerical error, this amendment to Form 4 is being filed to correct the transaction code in the reported transaction.
F2: As reported in the original Form 4, reflects the release of restricted stock units that were previously reported on a Form 4.
RIGEL PHARMACEUTICALS INC
Report date July 08, 2026 · Filed July 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,025 |
Reported balance
After 2026-07-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 24,400 · Balance 35,025 F1: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from July 8, 2026, with the first annual vest occurring on July 8, 2027. F2: Amount has been adjusted to reflect the cancellation of 5,750 restricted stock units for no consideration, which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d) promulgated under the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from July 8, 2026, with the first annual vest occurring on July 8, 2027.
F2: Amount has been adjusted to reflect the cancellation of 5,750 restricted stock units for no consideration, which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d) promulgated under the Securities Exchange Act of 1934, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2017 Filed Jul 31, 2017 21:25 UTC | NEOGENOMICS INC NEO · Entity 2096 | PurchaseCommon Stock | 20,000 | $9.19 | $183,800.00 |
DisclosureSEC source: 0001209191-17-046748 · doc4.xml · nonDerivative · entry 1 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,782 F1 · price: Represents the average purchase price of shares purchased on July 27, 2017. Read SEC document |
| May 30, 2017 Filed May 31, 2017 01:09 UTC | NEOGENOMICS INC NEO · Entity 2096 | ConversionRestricted Stock · Derivative | 5,072 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036314 · doc4.xml · derivative · entry 4 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,072 shares Expires 2017-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · kind: Restricted stock has vested and restricted stock certificate issued for shares of the company's common stock. F4 · derivative.exercise_date: 1,690.6 shares will vest on September 30, 2016 and thereafter, 1,690.7 shares will vest on the last day of each calendar quarter for the next two fiscal quarters up to March 31, 2017. Read SEC document |
| May 30, 2017 Filed May 31, 2017 01:09 UTC | NEOGENOMICS INC NEO · Entity 2096 | ConversionRestricted Stock · Derivative | 2,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036314 · doc4.xml · derivative · entry 3 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,150 shares Expires 2017-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · kind: Restricted stock has vested and restricted stock certificate issued for shares of the company's common stock. F3 · derivative.exercise_date: 537.5 shares will vest on June 30, 2016 and thereafter, 537.5 shares will vest on the last day of each calendar quarter for the next three fiscal quarters up to March 31, 2017. Read SEC document |
| May 30, 2017 Filed May 31, 2017 01:09 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 7,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036314 · doc4.xml · nonDerivative · entry 2 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2017 Filed May 31, 2017 01:09 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock · Derivative | 8,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036314 · doc4.xml · derivative · entry 8 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,667 Underlying: Common Stock · 8,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F8 · derivative.exercise_date: The restricted stock will vest as follows; 2,166 units at June 30, 2017 and thereafter, 2,167 shares will vest on the last day of each calendar quarter for the next three fiscal quarters up to March 31, 2018. F9 · derivative.expiration_date: These restricted stock units will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
| May 25, 2017 Filed May 31, 2017 01:09 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $7.27 Strike: $7.27 | $72,700.00 |
DisclosureSEC source: 0001209191-17-036314 · doc4.xml · derivative · entry 7 HANNAH ALISON L. · CIK 0001645600 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2022-05-25 F7 · derivative.exercise_date: On May 25, 2017, Alison Hannah was granted 10,000 stock options. The options vest ratably on the next three anniversary dates of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.